Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02429505|
Recruitment Status : Withdrawn (This study was COMPLETED, but no patients were enrolled.)
First Posted : April 29, 2015
Last Update Posted : August 28, 2020
|Condition or disease||Intervention/treatment|
Objective: The purpose of this observational study is to fulfill PMR 2127-4 for the miltefosine NDA (204684): implement a higher-weight-patient registry for the time period Mar 2015-Mar 2020.
Study Design: This study is a prospective observational study in which patients undergoing treatment for leishmaniasis with Impavido in the US and who weigh > 75 kg can volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.
Population: Leishmaniasis patients treated with Impavido who weigh more than 75 kg.
Drug name: Impavido (50 mg capsules). Dosing regimen: as per the Impavido Product Label
Study Procedures: Patients who weigh more than 75 kg will become aware of the Impavido Higher-Weight Patient Registry via the Impavido website. By calling 1-866-588-5405, the patient will be connected to the Impavido Higher-Weight Patient Registry Coordinating Center. A trained staff member will acquaint the patient with the goals and procedures of the study. If the patient tentatively agrees to participate in the study over the telephone, the patient will be mailed information forms, the Consent/Assent Forms, and the Consent for the patient's physician to release medical information. Receipt of the two signed Consent and/or Assent Forms by the Coordinating Center will signify patient consent. The Coordinating Center will contact the patient's physician at the end of treatment, and at 1, 3, and 6 months after completing treatment, to collect data on efficacy and adverse effects (only during treatment).
Sample Size and Study Duration: Estimated 3-10 patients per year for 5 years.
Efficacy Adverse effects
Analysis: Baseline data, compliance to prescribed treatment, and outcomes will be reported for individual patients and for all patients.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||0 participants|
|Target Follow-Up Duration:||6 Months|
|Official Title:||Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry|
|Actual Study Start Date :||July 2015|
|Actual Primary Completion Date :||March 2020|
|Actual Study Completion Date :||March 2020|
Miltefosine : target of 2.5 mg/kg/day for 28 days. Patients 45 kg or greater were to receive one 50 mg capsule 3 times daily for 28 consecutive days. This prospective observational study in which patients undergoing treatment for leishmaniasis with miltefosine in the United States who weighed >75 kg could volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.
miltefosine: target 2.5 mg/kg/day for 28 days
Other Name: Impavido
- Number of patients cured [ Time Frame: 6 months ]Determination of possible relationship of lower mg/kg daily doses of miltefosine and efficacy
- Number of patients with adverse effects [ Time Frame: 6 months ]Adverse events including symptoms and laboratory parameters (if available)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02429505
|United States, Maryland|
|Fast-Track Drugs and Biologics, LLC|
|Poolesville, Maryland, United States, 20837|
|Principal Investigator:||Janet Ransom, PhD||Fast Track Drugs and Biologics LLC|